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R9 ISOLATION PROCEDURE, SPECIES IDENTIFICATION
AND CLINICAL SIGNIFICANCE OF ASPERGILLUS SPP.,
SCEDOSPORIUM SPP., AND OTHER FILAMENTOUS FUNGI IN
CYSTIC FIBROSIS
G. Manno. Microbiology Laboratory, G. Gaslini Children’s Hospital Research
Institute, University Department of Paediatrics, Genova, Italy
Aspergillus fumigatus is the most common agent associated of airways colonization
in CF, it may cause various diseases including asthma, bronchitis and aspergilloma,
as well as invasive aspergillosis after lung transplantation. The most relevant clinical
form in CF patients remains allergic broncho-pulmonary aspergillosis (ABPA).
Other ﬁlamentous fungi are increasingly reported in CF, such as Scedosporium
apiospermum and some Aspergillus spp., particularly Aspergillus ﬂavus, Aspergillus
terreus, Aspergillus niger and Aspergillus nidulans which may be found transiently.
Scedosporium apiospermum is now recognized as an important colonizer of the
airways in CF patients, but little is known about the prevalence of non-fumigatus
Aspergillus species. Some of these fungi may be responsible for allergic broncho-
pulmonary disease similar to ABPA. The microbiological diagnosis usually relies
on direct microscopic examination and culture of CF sputum samples. However,
at present, there is no standardization of mycological examination of CF samples,
the culture media used, as well as temperature or incubation times. The absence
of selective media, as an insufﬁcient incubation time, may hamper the recovery of
some species like Scedosporium apiospermum which is usually associated to the
more rapidly growing fungus Aspergillus fumigatus.
Different rate of FF occurrence are described in CF patients in Europe (France, Ger-
many, Spain, etc.) but, at the moment, very little information are available from Italy.
From 1/1/2007 to 30/09/2007, 35/220 (15.9%) of pts attending the CF Centre
of Genova where colonized by ﬁlamentous fungi. The species distribution was:
A. fumigatus (64%), A. ﬂavus (25%), S. apiospermum (9%) others (2%).
R10 A PATIENT-ORIENTED LABORATORY MODEL FOR CYSTIC
FIBROSIS (CF)
E. Fiscarelli, G. Ricciotti, P. Campagnano, A. Angioni, F. Callea. Laboratory
Department Pediatric Hospital Bambino Gesu`, Rome, Italy
The Department of Pathology and Laboratory Medicine of the Children’s Hospital
Bambino Gesu` is developing a project of “clinicization” that is leading to the tran-
sition of the traditional concept of Department into an interdepartimental network.
That implies the evolution of the academic deﬁnition of department towards a
deﬁnition of “patient-centered” department.
A series of clinico-laboratory projects are being experienced, the prototype is the
Cystic Fibrosis (CF) model.
In this model the patient represents the center of the CF universe, around which
are rotating the pertinent and competent clinical units from one side and the CF
Laboratory from the other side. Interaction and communication take place by a
directional ﬂow passing through the CF patient.
The CF Laboratory is innovative in that it carries out both clinical and laboratory
work, either diagnostic or research.
The clinical activities consist in providing a qualiﬁed reception in a comfortable
environment to patients and families by an informative and formative approach
before performing the sweat test and a genetical counseling after the results of the
various diagnostic tests.
To optimize the results the sweat test is carried out by experienced medical personnel
and nurses.
The CF Lab consists of an integrated team from four specialized Labs: Molecular
Genetics where gene mutations are searched, a speciﬁc Microbiology Lab for
cultural and sensibility tests, a section of Chemical Chemistry for analytical
determination and a dedicated histopathologist with special interest in CF.
Laboratory rounds and participation of Lab staff members into clinical grand rounds
are promoting the clinical attitude of the participants, and are expected to contribute
to the continuous improvement of the safety and quality care of CF patients.
R11 FROM RESEARCH TO CLINICAL PRACTICE. RCTs AND THEIR
EXTERNAL VALIDITY
L. Pagliaro. Professor Emeritus of Internal Medicine, University of Palermo,
Palermo, Italy
Patient care and outcomes could be improved if the knowledge from research was
better translated into practice. It has been estimated that 30−40% of patients do
not receive treatments of proven effectiveness, whereas 20−25% receive treatments
that are unnecessary or potentially harmful. This situation is in part due to two
translational blocks that thwart the passage from basic research to clinical research,
eg RCTs (type 1 translational block), and from clinical research and RCTs to clinical
practice (type 2 translational block). Frequent information gaps due to inadequate
external validity contribute substantially to the translational roadblock between
RCTs and clinical practice (type 2 translational block). The external validity of
an RCT regards the information needed to apply the trial results in the appropriate
patients and settings, but it is often neglected, inadequate and unclear. Inclusion and
exclusion criteria; ratio between randomized and eligible patients; heterogeneity,
baseline risk and comorbidity of patients; selection of participating centres and
researchers; rate and reasons of discontinuation: this is an incomplete list of the
major requirements of external validity. When the information on these (and other)
areas is inadequate or unclear, clinicians’ uncertainty and underuse or even misuse
of treatments are the consequences. The conclusions are that:
Trialists should pay to the external validity the same attention and completeness
of information they usually pay to the internal validity. Pre-established subgroup
analyses in megatrials implying patients’ heterogeneity (eg, due to comorbidity)
could be of use to guide the trial application in practice.
Clinicians should take into account the limitations of the RCTs before applying their
results, perhaps using guidelines assembling the full evidence available in order to
compensate the lack of information of the individual RCT of interest.
R12 EVIDENCE BASED MEDICINE – ONE AID IN PROVIDING GOOD
CF CARE
J. Littlewood. UK CF Trust & Hon. Paediatrician, Regional Paediatric CF Unit,
St James’s University Hospital, Leeds, United Kingdom
The survival of people with cystic ﬁbrosis has steadily improved over the years
due to increasingly effective nutritional and antibiotic treatment for the secondary
effects of the basic defect. The care the patient receives from an early age is the
main determinant of health, quality of life and length of survival; but numerous
studies show major differences between CF Centres reﬂecting different patterns of
care. The features of early management later associated with better lung function
include early diagnosis by screening, lack of symptoms and higher weight for
age at diagnosis, more clinic visits, respiratory cultures, intravenous antibiotics,
corticosteroids and mucolytics.
An information revolution has taken place over the past 10−15 years including
the growth of Evidence Based Medicine deﬁned as “the conscientious explicit and
judicious use of current best evidence in making decisions about care of individual
patients”. There are now Systematic Reviews by the Cochrane Collaboration on
more than 40 areas of treatment for CF and more in preparation. These make a
variable contribution to CF care but are often more a statistical analysis of the
methodology of the published trials rather than a practical help to the clinician –
most call for further randomized controlled trials. Although a useful record of
published work, lack of large randomized controlled trials on some areas of
treatment where beneﬁt is nevertheless quite obvious to the experienced clinician,
may delay by years the introduction of treatments later proved to be very effective
e.g. the early eradication treatment of Pseudomonas aeruginosa.
So although Evidence Based Medicine has made and continues to make a signiﬁcant
contribution to CF care, it should be regarded as but one aid to better CF care – one
additional aid to the expertise of experienced staff at CF Centres; expertise that has
been acquired over many years of treating people with CF.
R13 A NEW MODEL OF CF DISEASE: NO F508, NO KINASE?
A. Mehta, K.J. Treharne, A. Winter, R. Langley, Z. Xu1, J.H. Chen1,
D.N. Sheppard1, K. Kunzelmann2, presented by AM on behalf of authors
in 1Bristol and 2Regensburg Universities. Maternal & Child Health Sciences,
University of Dundee, Ninewells Hospital & Medical School, Dundee, United
Kingdom
Protein kinase CK2 is an essential heterodimer (a2b2) whose constitutive activity
controls inﬂammation, cancer and infection; unexplained hallmarks of CF disease.
The deletion of only one amino acid (F, phenylalanine 508) causes most cystic
ﬁbrosis (CF) and our data connects this F508-CFTR region with a malfunctioning
protein kinase binding site and suggest that DF508 induces a kinase-opathy. We
noticed immediately C terminal to F508 lies a potential CK2 consensus motif
(F508GVS511YDE; target serine, S, plus locating motif DE) and tested the idea
that F508 is needed for CK2 function towards CFTR and vice versa.
Methods: Treharne et al J Biol Chem 2007 & Am J Physiol 1994 using models of
CFTR/CK2 function (confocal, oocytes, single channel CFTR kinetics) coupled to
CK2 assay in apical membrane samples and WT (HBE) and homozygous DF508
(CFBE) cell lines.
Results: Compared to HBE membranes containing WT-CFTR, CFBE membrane
blots contain no detectable catalytic CK2a, CK2b, unaffected) without affecting
PKA/PKC. Thus membrane local CK2 is absent in CF (conﬁrmed by activity assay).
Further, unlike in wild-type nasal epithelial biopsies, those from DF508 CF patients
do not localise CK2a to the apical membrane (n>3). In oocytes co-expressing
human WT CFTR with human CK2, CFTR (but not DF508-CFTR) closes by
